Cerevel rises as Parkinson's drug improves symptom control in late-stage trial

Cerevel Therapeutics Holdings

18/04/2024 13:10

** Shares of drug developer Cerevel Therapeutics  CERE.O  
rise 1.4% to $42.20 premarket
    ** Co says its experimental Parkinson's disease drug
tavapadon improved symptom control in patients when tested as an
add-on therapy to levodopa, the standard of care, in a
late-stage study
    ** CERE will share additional data from late-stage trials
testing the once-daily treatment tavapadon as a monotherapy in
the second half of 2024
    ** Up to last close, stock down 1.9% YTD

 (Reporting by Puyaan Singh)
 ((Puyaan.Singh@thomsonreuters.com;))